Table 4.

Top 10 most common treatments during each of the first four lines of therapy in Optum® De-Identified Clinformatics

Treatment line	Therapy/treatment	Patient count	Rank in treatment line	% of patients in treatment line
1 (n = 5837)	Behavioral and special therapy	3852	65.99%	1
	Centrally acting sympathomimetics	971	16.64%	2
	Selective serotonin reuptake inhibitors	923	15.81%	3
	Antipsychotics	591	10.13%	4
	Anticonvulsant	518	8.87%	5
	Imidazoline receptor agonists	447	7.66%	6
	Other (atypical) Antipsychotics	416	7.13%	7
	Other antidepressants	254	4.35%	8
	Hypnotics and sedatives	203	3.48%	9
	Anxiolytics (Excluding BZO)	193	3.31%	10
2 (n = 3527)	Behavioral and special therapy	1556	26.66%	1
	Centrally acting sympathomimetics	958	16.41%	2
	Selective serotonin reuptake inhibitors	881	15.09%	3
	Antipsychotics	589	10.09%	4
	Imidazoline receptor agonists	506	8.67%	5
	Anticonvulsant	466	7.98%	6
	Other (atypical) Antipsychotics	404	6.92%	7
	Other antidepressants	218	3.73%	8
	Hypnotics and sedatives	192	3.29%	9
	Anxiolytics (excluding BZO)	185	3.17%	10
3 (n = 2757)	Behavioral and special therapy	1088	18.64%	1
	Selective serotonin reuptake inhibitors	851	14.58%	2
	Centrally acting sympathomimetics	774	13.26%	3
	Antipsychotics	594	10.18%	4
	Imidazoline receptor agonists	491	8.41%	5
	Anticonvulsant	406	6.96%	6
	Other (atypical) Antipsychotics	396	6.78%	7
	Other antidepressants	241	4.13%	8
	Anxiolytics (excluding BZO)	178	3.05%	9
	SNRI	96	1.64%	10
4 (n = 2066)	Behavioral and special therapy	738	12.64%	1
	Selective serotonin reuptake inhibitors	694	11.89%	2
	Centrally acting sympathomimetics	581	9.95%	3
	Antipsychotics	515	8.82%	4
	Imidazoline receptor agonists	405	6.94%	5
	Anticonvulsant	386	6.61%	6
	Other (atypical) Antipsychotics	350	6.00%	7
	Other antidepressants	238	4.08%	8
	Anxiolytics (excluding BZO)	170	2.91%	9
	SNRI	91	1.56%	10